julie brahmer, md, on the level of pd-l1 expression in selecting the appropriate agent in nsclc
Published 8 years ago • 22 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
0:35
julie brahmer, md, provides practical advice related to pd-l1 testing in nsclc patients
-
0:47
david ettinger, md, talks about levels of pd-l1 expression and agent selection
-
1:53
dr. brahmer on the role of pd-1 and pd-l1
-
1:21
julie brahmer, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
1:15
dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc
-
0:41
julie brahmer, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
1:43
dr. brahmer explains pd-1 and pd-l1
-
26:02
doctors discuss: immunotherapy in lung cancer
-
5:03
tumour immunology and immunotherapy
-
2:55
how keytruda cancer treatment works (update)
-
51:55
the truth about palliative care in oncology with dr. janet abrahm
-
0:58
dr. julie r. brahmer on immunotherapy development in lung cancer
-
1:21
dr. julie brahmer on the pd-1 targeted immunotherapy bms-93655 clinical trial
-
1:41
dr. goldberg on pd-l1 as a biomarker in lung cancer
-
2:05
cancer immunotherapy in lung cancer discussed by dr. julie brahmer
-
0:31
copy of dr. brahmer on the role of immunotherapy in metastatic nsclc
-
0:55
laura chow, md discusses the role of pd-l1 testing in scchn
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
1:05
dr. brahmer on the impower150 trial in nsclc
-
1:31
dr. brahmer on the role of immunotherapy in metastatic nsclc
-
1:41
dr. brahmer discusses second-line pembrolizumab in nsclc
-
0:19
copy of dr. brahmer on immunotherapy in stage iv nsclc